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What are cost–effectiveness thresholds?
The main results of a cost–effectiveness analysis – in which 
the costs and outcomes of alternative policy options are 
compared – are cost–effectiveness ratios. In the field of 
health, a cost–effectiveness ratio usually represents the 
amount of additional health gained for each additional unit 
of resources spent. The makers of health policy initially 
used cost–effectiveness analyses for priority setting, in their 
attempts to ensure that the greatest possible health benefits 
were achieved given the available budget. Many countries 
currently use cost–effectiveness analyses and the resultant 
cost–effectiveness ratios to guide their decisions on resource 
allocation and to compare the efficiencies of alternative 
health interventions.
A cost–effectiveness threshold is generally set so that the 
interventions that appear to be relatively good or very good 
value for money can be identified. There are several types of 
threshold. In health-related analyses, a willingness-to-pay 
threshold represents an estimate of what a consumer of health 
care might be prepared to pay for the health benefit – given 
other competing demands on that consumer’s resources. There 
are also supply-side thresholds that take resource allocation 
into account – e.g. estimates of the health foregone because 
an insurance company or other provider spends some of its 
available budget on a new intervention and is therefore forced 
to reduce its funding of older interventions.
In considering the choice of the type of cost–effectiveness 
threshold to use, the concept of opportunity cost may be the 
one most relevant to providers who are primarily concerned 
with using the available resources to improve health. In con-
sidering the implementation of a new intervention, decision-
makers need estimates of both the health that might be gained 
elsewhere through the alternative use of the resources needed 
for the new intervention and the health that is likely to be lost 
if the new intervention is not used.
Recent claims about the misapplication of cost–effective-
ness thresholds1 are well founded. However, we feel that the 
implication that the World Health Organization’s (WHO’s) 
Commission on Macroeconomics and Health’s cost–effective-
ness thresholds are intended to be used as the explicit criteria 
for health decisions at national level – ignoring all other 
policy-relevant evidence – is incorrect.
Thresholds based on gross domestic product
The most commonly cited cost–effectiveness thresholds 
are those based upon a country’s per-capita gross domestic 
product (GDP) and the Commission on Macroeconomics 
and Health’s corresponding estimate of the economic value 
of a year of healthy life.2 As ill health has a negative economic 
impact, investments in health can contribute to economic 
development. The commission, in trying to encourage invest-
ment in health, has suggested that all countries should map 
out a path to universal access to essential health services, 
increase domestic financing for health and include economic 
considerations in their attempts to identify health priorities.2 
The commission also suggested that it was reasonable to spend 
the estimated value of a year of healthy life, per capita, on an 
intervention that led to a mean of at least one additional year 
of healthy life per capita.2
The commission’s GDP-related cost–effectiveness thresh-
olds were based on assumptions about leisure time, non-health 
consumption, longevity and health-related quality of life. They 
can be compared to measures – e.g. the so-called value of a 
statistical life – that are based on individuals’ actual choices3 
(DT Jamison, personal communication, 2015) and represent 
an estimate of an individual’s willingness to pay to extend their 
healthy life by one year. There has been criticism of the com-
mission’s focus on GDP-based thresholds, since “people value 
life in dimensions that extend beyond income”.4 However, the 
cost thresholds published by the commission in 20012 are simi-
Abstract Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost–
effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost–effectiveness thresholds 
allow cost–effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization’s 
Commission on Macroeconomics in Health suggested cost–effectiveness thresholds based on multiples of a country’s per-capita gross 
domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have 
been used as decision rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level 
shows them to lack country specificity and this – in addition to uncertainty in the modelled cost–effectiveness ratios – can lead to the wrong 
decision on how to spend health-care resources. Cost–effectiveness information should be used alongside other considerations – e.g. budget 
impact and feasibility considerations – in a transparent decision-making process, rather than in isolation based on a single threshold value. 
Although cost–effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop 
a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil 
society organizations and patient groups, and is transparent, consistent and fair.
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lar to the more detailed – and, perhaps, 
more reliable – estimates published over 
a decade later.5
In 2005, authors writing on behalf 
of WHO’s Choosing Interventions that 
are Cost–Effective project (WHO-
CHOICE) suggested that “interventions 
that avert one DALY [disability-adjusted 
life-year] for less than average per 
capita income for a given country or 
region are considered very cost–effec-
tive; interventions that cost less than 
three times average per capita income 
per DALY averted are still considered 
cost–effective; and those that exceed 
this level are considered not cost–effec-
tive”.6 Although they may indicate that 
an intervention is cost–effective or very 
cost–effective, none of these thresholds 
should be used, alone, as a decision rule 
for funding or as a measure of afford-
ability. They are simply an indication 
that, in a given setting, an intervention 
may represent poor, good or very good 
value for money.
As used by WHO-CHOICE, the 
Commission on Macroeconomics and 
Health’s GDP-based thresholds were 
only intended to be generic global 
norms. For example, the list of inter-
ventions given in Appendix 3 of the 
WHO’s Global Action Plan for the 
Prevention and Control of Noncom-
municable Diseases 2013–20207 – i.e. 
the list of interventions sometimes 
referred to as the best buys – represents 
a menu of medical and public health 
interventions to consider in a range of 
settings. Although this list was partly 
based on value for money – in terms of 
GDP-based cost–effectiveness thresh-
olds – it was also based on affordability, 
feasibility and other criteria. In a similar 
manner, in work carried out on behalf of 
WHO-CHOICE, GDP-based thresholds 
were used to categorize interventions as 
cost–effective or very cost–effective but 
the intention was only to guide policy-
makers on value for money.8 It was 
always assumed and intended that other 
considerations relevant to local settings 
would be used in decision-making.
Interpreting WHO-CHOICE’s 
results
The main objective of WHO-CHOICE 
is to assist with priority setting across an 
entire benefits package – and, ultimately, 
achieve universal health coverage. Other 
related programmes for priority setting 
– e.g. the SMART vaccine project9 – use 
the results of cost–effectiveness analysis 
only to make incremental or marginal 
decisions about the addition of single 
interventions to an existing benefits 
package. Where the primary goal of 
a health system is the optimization of 
population health, it can be important 
to use an approach such as that followed 
by WHO-CHOICE – and its generalized 
cost–effectiveness analysis – to decide 
which set of interventions, out of a larger 
group of feasible options, offer the best 
value for money. The addition of single 
interventions one at a time, based on 
incremental analyses, may not result in 
the optimal use of resources. However, 
given that many systems already have 
an existing package of interventions, in 
some settings there is clearly still a role 
for incremental analysis.
Misuse of thresholds
Many factors influence the results of 
cost–effectiveness analyses – e.g. the 
data used to estimate costs and effects, 
the choice of comparator and whether 
or not subgroups of the target popula-
tion are analysed. Variations in the 
inputs can have substantial effects on 
the estimate of a cost–effectiveness 
ratio. If the analyses do not reflect the 
policy context accurately, overreliance 
on cost–effectiveness ratios and a fixed 
cost–effectiveness threshold, to guide 
decision-making, may result in the 
wrong decisions being made.
At a technical level, it is important 
to note that cost–effectiveness ratios 
derived from economic modelling are 
simply estimates – generally based on 
several assumptions – produced to 
indicate the potential value for money 
of one or more interventions. The con-
struction of economic models is prone 
to problems and errors,10–15 but such 
models can still be a valuable input for 
decision-making if well-constructed 
and validated. However, even well-
constructed models can produce a range 
of estimates depending on the assump-
tions adopted and the formulation of 
the policy question being evaluated. Use 
of a rigid cost–effectiveness threshold 
to determine funding decisions may 
simply encourage the interested parties 
to tailor their estimates so that they 
trigger funding.
Even if estimated accurately, ge-
neric GDP-based cost–effectiveness 
ratios – or other estimates of willing-
ness to pay – do not provide informa-
tion on affordability, budget impact or 
the feasibility of implementation. In 
Peru, a contextualised WHO-CHOICE 
analysis of breast cancer treatments 
concluded that addition of trastuzumab 
to a package of interventions would be 
cost–effective – i.e. cost less than three 
times the per-capita GDP per DALY 
averted.16 However, the costs of adding 
trastuzumab would exceed Peru’s entire 
budget for breast cancer treatment.16
Similarly, several analyses have 
concluded that sofosbuvir is a cost–ef-
fective treatment option for some sub-
groups of patients with hepatitis C.17–19 
For example, using a cost– effectiveness 
threshold of 100 000 United States dol-
lars per DALY averted, it was estimated 
that 83% of hepatitis C patients in the 
United States of America would be 
eligible for treatment with the drug.17 
However, treatment of all the eligible 
patients would require a 4% increase in 
national pharmaceutical spending. Such 
an increase is probably unaffordable and 
more cost–effective interventions would 
probably be crowded out if sofosbuvir 
were to be offered on such a large scale.
In the detection of tuberculosis, the 
use of GeneXpert (Cepheid, Sunnyvale, 
United States of America) – a molecular 
test for the deoxyribonucleic acid of 
Mycobacterium tuberculosis – is consid-
ered to be a cost–effective intervention 
that has already been implemented in 
South Africa.20 Widespread use of the 
test not only has high initial costs – in 
terms of laboratory space, GeneXpert 
machines and staff training – but also 
depends on a consistent electrical sup-
ply.21 In the absence of basic amenities 
such as regular electricity supply, any 
GeneXpert machines are likely to remain 
underused and unable to achieve their 
modelled levels of efficiency and cost–ef-
fectiveness.
From evidence to decision-
making
The use of cost–effectiveness ratios 
in decision-making remains an area 
without consensus.15 Our view is that 
a fixed cost–effectiveness threshold 
should never be used as a stand-alone 
criterion for decision-making. Above all, 
the indiscriminate sole use of the most 
common threshold – of three times the 
per-capita GDP per DALY averted – in 
national funding decisions or for set-
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ting the price or reimbursement value 
of a new drug or other intervention 
must be avoided. WHO-CHOICE has 
never recommended this practice, which 
would be a distortion of the intention 
and meaning of the GDP-based thresh-
olds proposed by the Commission on 
Macroeconomics and Health.
If a single fixed cost–effectiveness 
threshold is not to be used – at least, 
not alone – what are the alternatives? In 
the development of clinical guidelines, 
evidence-to-decision frameworks have 
been developed to guide decision-mak-
ing.22,23 Explicit guidance on the inclu-
sion of fairness in the decision-making 
needed to achieve universal health 
coverage has been published.24 Multi-
criteria decision analysis frameworks 
have also been suggested.25
Based on our experience, we be-
lieve that countries should consider 
establishing a context-specific process 
for decision-making that is supported 
by legislation, has stakeholder buy-in 
and is consistent, fair and transpar-
ent. While cost–effectiveness ratios are 
undoubtedly informative in assessing 
value for money – from either the sup-
ply or demand side – they also need to 
be considered alongside affordability, 
budget impact, fairness, feasibility and 
any other criteria considered important 
in the local context. The Norwegian 
Committee on Priority Setting has 
proposed the use of three criteria – i.e. 
health benefit, health loss and resources 
– and suggested differentiating thresh-
olds across the different categories of 
potential health loss.26
Decision-makers need to have 
sufficient confidence in the quality 
and reliability of cost–effectiveness 
estimates, which, in turn, requires 
sufficient local capacity for the ap-
praisal  of  economic models and 
their outputs. In health systems that 
have these components in place, a 
more meaningful local and explicit 
cost–effectiveness threshold might 
eventually emerge (Box 1). To ensure 
better health outcomes and optimal 
value for money, decision-makers 
need to use all the relevant data and 
estimates wisely.
Competing interests: None declared.
Box 1. Experiences with the use of explicit cost–effectiveness thresholds
Australia
A retrospective analysis of the recommendations of the Pharmaceutical Benefits Advisory 
Committee found that the implied threshold for a positive recommendation was 46 400 
Australian dollars – i.e. 1.35 times the per-capita gross domestic product (GDP) in 1999 – per 
quality-adjusted life-year (QALY) gained.27 However, it was noted that there was, in fact, no fixed 
threshold and that other aspects of the related evidence – e.g. confidence in the clinical data 
– appeared to have been just as important to the committee as estimated cost–effectiveness 
ratios.27,28 The committee has experts who review all submissions and has the legislative mandate 
to provide advice on reimbursement prices.
Poland
In 2012, for its decisions on reimbursing the costs of new pharmaceuticals, Poland legislated 
a cost–effectiveness threshold of three times the per-capita gross GDP per QALY gained.29 
Manufacturers who submit applications for reimbursement of the costs of new products are 
required to provide fully-functional models that allow the evaluation of all the input parameters. 
Although the impact of the threshold is not yet clear, the prices paid in Poland for certain products 
appear to be higher than the mean values for the European Union.30
Thailand
In 2007, the subcommittee responsible for the development of Thailand’s national list of 
essential medicines set a threshold of 100 000 Thai baht – i.e. 0.8 of the per-capita GDP – per 
QALY gained.31 This threshold, which applies specifically to medicines included on the essential 
medicines list, has been a particularly powerful tool in price negotiations. For example, it has 
resulted in price decreases, in Thailand, of 72% for tenofovir and 69% for oxaliplatin.32 Health 
technology assessments are commissioned through the Health Intervention and Technology 
Assessment Programme and made independently of any pharmaceutical company. Decisions 
on the benefit package are made by the National Health Assembly, using societal values, and 
cost–effectiveness thresholds are therefore not the only aspect taken into consideration.33
United Kingdom of Great Britain and Northern Ireland
Since at least 2000, the United Kingdom’s National Institute for Health and Care Excellence has 
used an explicit cost–effectiveness threshold of between 20 000 and 30 000 pounds sterling (£) 
– i.e. 1.18 and 1.76 times the per-capita GDP in 2000, respectively, but only 0.70 and 1.04 
times the corresponding product for 2015, respectively – per QALY gained. If the incremental 
cost–effectiveness ratio for a new technology falls below £20 000 per quality-adjusted life-
year gained, that technology is generally recommended for purchase by the national health 
system. Technologies that appear less cost–effective may still be recommended if they are for 
end-of-life care or for diseases associated with short life expectancies that would be extended 
by the technology. However, when some cancer drugs were consistently found to have cost–
effectiveness ratios of more than £30 000 per QALY gained – and were therefore rejected by 
the National Institute for Health and Care Excellence – an alternative funding mechanism was 
established. The National Institute’s effective cost–effectiveness threshold – reflecting the likely 
impact of expenditure on both mortality and morbidity – has been estimated to be £12 936 per 
QALY gained. This relatively low value probably reflects the displacement of more cost–effective 
activities by new approvals.34,35
صخلم
تايبلسلاو تايبايجلإا :ةفلكتلا ةيلاعفل ةيدلحا ميقلا
 لئاصلحاو  فيلاكتلا  ينب  ةنراقملل  ةفلكتلا  ةيلاعف  ليلاتح  مدختسُت
 بسن  نم  ةبسن  لك  لثتم  .ةليدبلا  تاسايسلا  تارايخ  نع  ةتجانلا
 بستكلما  فياضلإا  يحصلا  ىوتسلما  مجح  ةتجانلا  ةفلكتلا  ةيلاعف
 ةيلاعفل ةيدلحا ميقلا حيتتو .دراولما نم ةيفاضإ ةدحو كلاهتسا نم
 ةميق  وأ  ةديج  ةميق  لثتم  يتلا  ةفلكتلا  ةيلاعف  بسن  ديدتح  ةفلكتلا
 ةحصلا  ةمظنلم  ةعباتلا  ةنجللا  تناكو  .لالما  لباقم  اًدج  ةديج
 في  تحترقا  دق  ةحصلا  لامج  في  ليكلا  داصتقلااب  ةينعلماو  ةيلماعلا
 تافعاضم  لىع  ًءانب  ةفلكتلا  ةيلاعفل  ةيدح  ميق  ءاشنإ  2001  ماع
 فيو  .دلابلا  في  )GDP(  ليحلما  جتانلا  لياجمإ  نم  درفلا  بيصن
 دعاوق  اهرابتعاب  ةيدلحا  ميقلا  هذه  مادختسا  مت  ،فورظلا  ضعب
 مدع وأ اهليوتم يغبني ةيحصلا تلاخدتلا يأ رايتخاب رارقلا ذاتخلا
 لىإ ةدنتسلما ةيدلحا ميقلا هذه مادختسا ةبرتج عقاو نأ لاإ .اهليوتم
 يرطقلا ىوتسلما لىع رارقلا ذاتخا تايلمع في ليحلما جتانلا  لياجمإ
 مدع  لىإ  ةفاضلإاب  اذه  .نادلبلا  في  ةيصصختلا  لىإ  رقتفت  انهأ  ينبي
 ذاتخا  لىإ  يدؤي  نأ  نكمي  ةيجذومنلا  ةفلكتلا  ةيلاعف  بسنب  ينقيلا
 يغبني  .ةيحصلا  ةياعرلا  دراوم كلاهتسا ةقيرط نأشب ئطاخ رارق
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Seuils de rentabilité: avantages et inconvénients
Les analyses de rentabilité permettent de comparer les coûts et les 
résultats de différentes options politiques. Chaque ratio coût-efficacité 
qui en découle indique l’importance des avantages supplémentaires 
pour la santé par unité supplémentaire de ressources dépensée. Les 
seuils de rentabilité permettent de déterminer les ratios coût-efficacité 
qui représentent une bonne ou une très bonne rentabilité. En 2001, la 
Commission macroéconomie et santé de l’Organisation mondiale de la 
Santé a suggéré des seuils de rentabilité définis d’après des multiples du 
produit intérieur brut (PIB) par habitant d’un pays. Dans certains pays, ces 
seuils ont servi de règles pour décider quelles interventions financer ou 
non. Cependant, l’expérience d’utilisation de ces seuils fondés sur le PIB 
dans les processus décisionnels des pays montre qu’ils ne tiennent pas 
compte des spécificités des pays; cela, ajouté à une certaine incertitude 
concernant la modélisation des ratios coût-efficacité, peut entraîner 
la prise de mauvaises décisions quant à l’utilisation des ressources 
sanitaires. Les informations sur la rentabilité des interventions devraient 
être prises en compte parallèlement à d’autres considérations, comme 
l’impact budgétaire et la faisabilité, dans le cadre d’un processus 
décisionnel transparent et non de façon isolée sur la base d’une seule 
valeur seuil. Bien que le caractère informatif des ratios coût-efficacité 
soit indéniable lorsqu’il s’agit d’évaluer la rentabilité des interventions, 
les pays devraient être encouragés à développer un processus de prise 
de décision spécifique au contexte, qui soit encadré par la législation et 
qui ait l’adhésion des parties intéressées, avec par exemple l’implication 
d’organisations de la société civile et de groupes de patients, et qui soit 
transparent, cohérent et équitable.
Резюме
Пороговые значения экономической эффективности: за и против
Анализ экономической эффективности применяется для 
сравнения затрат и результатов различных вариантов одной 
и той же стратегии. Во всех случаях соотношение затрат и 
эффективности дает представление о том, как будет происходить 
улучшение здоровья на единицу затраченных ресурсов. 
Пороговое значение экономической эффективности позволяет 
выявить такое соотношение затрат и эффективности, которое 
отвечает получению хороших или очень хороших результатов 
относительно затраченных средств. В 2001 году комиссия 
Всемирной организации здравоохранения по макроэкономике 
в здравоохранении порекомендовала пороговые значения 
экономической эффективности, основанные на параметрах 
валового внутреннего продукта на душу населения (ВВП) стран. 
В некоторых ситуациях эти пороговые значения использовались 
для принятия решения о том, какие меры по здравоохранению 
будут получать финансирование, а какие — нет. Однако опыт 
применения пороговых значений, основанных на величине ВВП 
стран, показал, что при этом не учитывается их специфика, и это 
в сочетании с неопределенностью в описании моделируемых 
затрат может способствовать принятию неверных решений 
о распределении средств на охрану здоровья. Информацию 
об экономической эффективности следует использовать 
с учетом других факторов, например влияния на бюджет и 
возможности осуществления, при этом процесс принятия 
решений должен быть прозрачным и выполняться не только на 
основе одного порогового показателя. Хотя соотношение затрат и 
эффективности, без сомнения, позволяет определенным образом 
оценить пользу от затраченных средств, следует поощрять страны 
на развитие прозрачным, честным и единообразным способом, 
учитывая их собственную ситуацию при разработке процесса 
принятия решений, который поддерживается законодательством 
и имеет заинтересованных акционеров, например гражданских 
ассоциаций или групп пациентов.
 تارابتعا  بناج لىإ ،ةفلكتلا  ةيلاعفب  ةقلعتلما  تامولعلما  مادختسا
 ىودلجا  ىدمو  ةينازيلما  يرثأت  تارابتعا  لاثلما  ليبس  لىع  ،ىرخأ
 تارارق  ذاتخا  نع  اًضوع  ةيفافشلاب  مستت  تارارق  ذاتخا  ةيلمع  في
 ةيلاعف بسن نأ نم مغرلا لىع .ةيدرف ةيدح ةميق لىإ ةدنتسم ةلزعنم
 عيجشت يغبني ،لالما لباقم ةميقلا ريدقت في كش لاب ةديفم ةفلكتلا
 تارارقلا ذاتخلا فورظلا عم ةبسانتم تايلمع دادعإ لىع نادلبلا
 ليبس  لىع  ،ةينعلما  تاهلجا  تررق  لاح  في  ،تاعيشرتلاب  ةموعدلما
 مستتو  ،ضىرلما  تاعوممجو  نيدلما  عمتجلما  تماظنم  كاشرإ  لاثلما
.ةيهزنو ةقستمو ةفافش انهأب تارارقلا هذه
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Resumen
Umbrales de rentabilidad: ventajas e inconvenientes
El análisis de rentabilidad se utiliza para comparar los costes y resultados 
de opciones políticas alternativas. Cada relación de rentabilidad resultante 
representa la magnitud de sanidad adicional obtenida por unidad 
adicional de recursos utilizados. Los umbrales de rentabilidad permiten la 
identificación de las relaciones de rentabilidad que representan un valor 
bueno o muy bueno del capital. En 2001, los umbrales de rentabilidad 
propuestos por la Comisión sobre Macroeconomía y Salud de la 
Organización Mundial de la Salud se basaron en múltiplos del producto 
interior bruto (PIB) per cápita de un país. En algunos contextos, se han 
utilizado estos umbrales para decidir qué intervenciones sanitarias 
financiar y cuáles no. No obstante, la experiencia con el uso de dichos 
umbrales basados en el PIB en los procesos de toma de decisiones a 
nivel nacional muestra la ausencia de especificidad según el país. Esto, 
además de la incertidumbre de las relaciones de rentabilidad modelo, 
puede dar lugar a una toma de decisiones equivocada sobre cómo 
emplear los recursos sanitarios. La información relativa a la rentabilidad 
debería utilizarse teniendo en cuenta otros factores (por ejemplo, 
el impacto presupuestario y aspectos de viabilidad) en un proceso 
transparente de toma de decisiones, en lugar de únicamente teniendo 
como referencia un solo valor del umbral. A pesar de que las relaciones 
de rentabilidad son indudablemente esclarecedoras a la hora de evaluar 
el valor del capital, es necesario fomentar que los países desarrollen un 
proceso específico del contexto apoyado por la legislación para tomar 
decisiones, como, por ejemplo, si las partes interesadas han aceptado 
la implicación de las organizaciones de la sociedad civil y grupos de 
pacientes y si es transparente, coherente y justa.
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